中材科技(002080.SZ):子公司南玻有限擬投資2.84億元推進工信部“2019年國家新材料檢測評價平台-複合材料行業中心項目”建設任務
格隆匯 10 月 8日丨中材科技(002080.SZ)公佈,根據公司的戰略與產業發展規劃,公司之全資子公司南京玻璃纖維研究設計院有限公司(以下簡稱“南玻有限”)擬投資2.84億元推進工信部“2019年國家新材料檢測評價平台-複合材料行業中心項目”建設任務,全面提升我國複合材料測試評價水平,打造具有全球核心競爭力和戰略影響力的世界一流的複合材料測試評價中心。
該項目主要面向航空航天、汽車輕量化、軌道交通、風電葉片等領域,開展高性能纖維、預製體和樹脂基複合材料的測試評價與認證服務,提供信息諮詢、標準化服務等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.